( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE  , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , 

 ISSN 2394-3211

Impact Factor: 6.222

 ICV - 79.57



Hajar Zhar*, Yassine Atbib, Aboubacar Sékou KABA, Youssef Moutaouakkil, Yasmina Tadlaoui, Yassir Bousliman


Introduction: The unit of retrocession of anticancer drugs at the Military Hospital of Instruction Mohammed V (HMIMV) Rabat ensures the dispensation of anticancer chemotherapy drugs to patients. The objective of this study is to quantify the losses of leftovers generated by the current mode of preparation of anticancer chemotherapies for our hospital establishment. Materials and Methods: This is a retrospective study that was conducted at the cancer drug retrocession unit of HMIMV in Rabat, Morocco between January and October 2020. The main analysis compared the actual cost of leftover preparations with the theoretical costs of leftover preparations if they were made in the care units. This analysis covered a set of 3000 chemotherapy preparations prescribed in the prescriptions. Results: During the 10 months of the study, 4,511 vials of the different molecules in the study were dispensed to patients, corresponding to a total of €480,518.07. From this number of vials used, we can save 1,779 vials per medical prescription, which represents an average of potential savings of around €56,572.50 (total cost of the remaining vials for 10 months*100/total amount of the expenses) This amount corresponds to 11.77% of the total amount of care granted to patients. The total cost of the remainders for 10 months is 56,572.50 euros, which corresponds to a total annual cost of 67,887.00 euros. TRASTUSUMAB, BEVACIZUMAB, BOTEZOMIB, AZACITIDINE, CETUXIMAB and PEMETREXED are the six molecules that represent the most losses among all our molecules studied. Conclusion: According to the financial elements found in our study, it is imperative to set up a centralized cytotoxic reconstitution unit (CCRU). The management of leftovers in this unit can generate significant savings depending on the molecules. Centralizing the preparation of anti-cancer drugs is of economic interest, by optimizing the management of leftovers. Our perspective is to be able to participate in this new setting up of the UCRC and to compare our results with those of the new installation.

Keywords: Retrocession, anti-cancer drugs, expensive drugs, loss, leftovers.

[Full Text Article]



  • New Issue Published

    Its Our pleasure to inform you that, EJPMR 1 October 2021 Issue has been Published, Kindly check it on


    OCTOBER Issue has been successfully launched on 1 October 2021.

  • EJPMR New Impact Factor

    Its our Pleasure to Inform you that EJPMR Impact Factor has been increased from  5.804 to 6.222, due to high quality Publication at International Level

  • Index Copernicus Value

    EJPMR Received Index Copernicus Value 79.57, due to High Quality Publication in EJPMR at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.


  • Article Invited for Publication

    Article are invited for publication in EJPMR Coming Issue

Google Scholar Indian Science Publications InfoBase Index (In Process) SOCOLAR, China Research Bible, Fuchu, Tokyo. JAPAN International Society for Research activity (ISRA) Scientific Indexing Services (SIS) Polish Scholarly Bibliography Global Impact Factor (GIF) (Under Process) Universal Impact Factor International Scientific Indexing (ISI), UAE Index Copernicus CAS (A Division of American Chemical Society) USA (Under Process) Directory of Open Access Journal (DOAJ, Sweden, in process) UDLedge Science Citation Index CiteFactor Directory Of Research Journal Indexing (DRJI) Indian citation Index (ICI) Journal Index (JI, Under Process) Directory of abstract indexing for Journals (DAIJ) Open Access Journals (Under Process) Impact Factor Services For International Journals (IFSIJ) Cosmos Impact Factor Jour Informatics (Under Process) Eurasian Scientific Journal Index (ESJI) International Innovative Journal Impact Factor (IIJIF) Science Library Index, Dubai, United Arab Emirates Pubmed Database [NLM ID: 101669306] (Under Process) IP Indexing (IP Value 2.40) Web of Science Group (Under Process) Directory of Research Journals Indexing Scholar Article Journal Index (SAJI) International Scientific Indexing ( ISI )